Sunday, May 3, 2015 Last update: 5:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Mylan Inc.

News articles for Mylan Inc.:

Monday, March 2, 2015

Monday, February 23, 2015

Monday, February 9, 2015

Monday, February 2, 2015

Thursday, January 29, 2015

Monday, January 26, 2015

Tuesday, January 20, 2015

Thursday, January 15, 2015

  • Mylan Launches Generic Epivir-HBV® Tablets
    PITTSBURGH, Jan. 15, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's Epivir-HBV(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application ... read more

Monday, January 5, 2015

  • Mylan Launches Generic Diovan® Tablets
    PITTSBURGH, Jan. 5, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of Novartis' Diovan(®) Tablets. Mylan received final approval from the U.S. Food and Drug ... read more

Wednesday, December 31, 2014

Monday, December 22, 2014

  • Mylan Launches First Generic Version of Vivelle-DOT®
    PITTSBURGH, Dec. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of Novartis' Vivelle-DOT(®). Mylan received final approval from the ... read more

Wednesday, December 17, 2014

  • Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
    PITTSBURGH, Dec. 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33(rd) Annual Healthcare Conference on Tuesday Jan. 13, 2015, in San Francisco. The presentation is scheduled ... read more

Thursday, December 11, 2014

  • Mylan Launches Generic Robaxin® Injection
    PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin(®). Mylan received final approval from the U.S. Food ... read more
  • Mylan Launches First Generic Version of Orapred ODT®
    PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT®. Mylan received final approval from ... read more

Wednesday, December 10, 2014

Monday, December 8, 2014

  • World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017
    PITTSBURGH and NEW YORK, Dec. 8, 2014 /PRNewswire/ -- World TeamTennis (WTT), the innovative leader in professional team tennis competition, and Mylan (Nasdaq: MYL), one of the world's leading pharmaceutical companies, today announced an extension of their title sponsorship agreement through 2017. http://photos.prnewswire.com/prnvar/20141208/162782 Mylan will continue to serve as ... read more

Thursday, December 4, 2014